The QualityStocks Daily Tuesday, November 22nd, 2022

Today's Top 3 Investment Newsletters

QualityStocks(COSM) $0.3275 +86.93%

MarketBeat(CING) $0.8700 +25.72%

StockEarnings(ANF) $22.6200 +21.42%

The QualityStocks Daily Stock List

Cosmos Holdings (COSM)

QualityStocks, The Stock Dork, TopPennyStockMovers, PoliticsAndMyPortfolio, OTC Markets Group, MarketBeat and Broad Street reported earlier on Cosmos Holdings (COSM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cosmos Holdings Inc. (NASDAQ: COSM) (FRA: V67) is a vertically integrated pharmaceutical firm that is engaged in the identification, acquisition, development and commercialization of genetic nutraceuticals, medical devices, over-the-counter medications and pharmaceuticals that improve patient outcomes and lives.

The firm has its headquarters in Chicago, Illinois and was incorporated in 2009, on July 21st. Prior to its name change in November 2013, the firm was known as Prime Estates and Developments Inc. It operates as part of the drug manufacturers-specialty and generic industry, under the healthcare sector. The firm has three companies in its corporate family and serves consumers around the globe.

The company has an extensive network of over 150 clients and vendors in Greece, the Netherlands, Poland, Sweden, Ireland, Singapore, France, Italy, Denmark, the United Arab Emirates, the United Kingdom and Germany. It operates through its subsidiaries, selling pharmaceutical products throughout Europe on wholesale. Its subsidiaries include Cosmofarm S.A., Decahedron Ltd and SkyPharm S.A. SkyPharm is also involved in the development and sale of its own branded nutraceutical product line. The company has distribution centers and offices in Harlow, U.K. and Thessaloniki, Greece.

The enterprise’s portfolio consists of over 70 product codes including minerals, vitamins and other herbal extracts used for health care and prevention needs. It also operates a fully automated warehouse system with a single A-frame type system, a pair of ROWA type systems and a trio of robotic systems.

The company’s recently announced financial results show significant increases in its revenues. It remains focused on strengthening its balance sheet, expanding geographically and penetrating more markets in the European Union. This will bring in additional revenues while also bolstering the company’s growth.

Cosmos Holdings (COSM), closed Tuesday's trading session at $0.3275, up 86.9292%, on 371,772,369 volume. The average volume for the last 3 months is 1.18M and the stock's 52-week low/high is $0.0675/$4.51.

Motorsport Games (MSGM)

The Online Investor, QualityStocks, MarketBeat and AwesomeStocks reported earlier on Motorsport Games (MSGM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Motorsport Games Inc. (NASDAQ: MSGM) is a motorsport network firm that is focused on the development and publishing of multi-platform racing video games.

The firm has its headquarters in Miami, Florida and was incorporated in August 2018. It operates as part of the electronic gaming and multimedia industry, under the communication services sector. The firm has twenty-seven companies in its corporate family and serves consumers around the world.

The company operates through the E-sports and Gaming segments. The E-sports segment is involved in organizing and facilitating e-sports events, competitions and tournaments for licensed racing games, as well as on behalf of other video game publishers and 3rd party video game racing series. On the other hand, the Gaming segment is involved in the development and publishing of interactive racing video games and entertainment services and content. The company operates as a Motorsport Network LLC subsidiary.

The enterprise provides video games for mobile platforms, personal computer platforms and game consoles through a number of digital and retail channels, which include downloadable and full-game content. It also provides motorsport racing series including BTCC (the British Touring Car Championship) and NASCAR. The enterprise is also an e-sports partner of choice for BTCC, Formula E, 24 Hours of Le Mans, NASCAR and the FIA World Rally Cross-Championship. It sells its video game products via various digital and retail channels.

The firm expects to accelerate its growth as well as increase its revenues significantly, which will help create value for its shareholders and bring in more investments into the firm.

Motorsport Games (MSGM), closed Tuesday's trading session at $6.8, up 51.1111%, on 1,189,993 volume. The average volume for the last 3 months is 62.175M and the stock's 52-week low/high is $4.29/$99.40.

Palisade Bio Inc. (PALI)

MarketBeat, StockOnion, QualityStocks, Profitable Trader Authority, PennyStockScholar, PennyStockProphet, Penny Pick Finders, OTCtipReporter, Mega Stock Alerts, HotOTC and Buzz Stocks reported earlier on Palisade Bio Inc. (PALI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Palisade Bio Inc. (NASDAQ: PALI) (FRA: 7NSA) is a clinical stage biopharmaceutical firm that is focused on the discovery, development and commercialization of oral therapies which target severe ailments linked to the breakdown of the mucosal barrier that protects the gastrointestinal tract.

The firm has its headquarters in Carlsbad, California and was incorporated in 2005. Prior to its name change, the firm was known as Seneca Biopharma Inc. It serves consumers around the globe.

The company develops therapies which help patients with chronic and acute gastrointestinal complications which were caused by post-operative digestive enzyme damage. Its mission is to develop new treatments for diseases with unmet medical needs. The company is in the process of finding and acquiring new assets, promising technologies and sciences which will provide meaningful therapies to patients.

The enterprise’s product portfolio comprises of a phase III-ready oral liquid serine protease formulation, a digestive enzyme inhibitor dubbed LB1148, which has been designed to preserve gut integrity during intestinal stress and hinder digestive enzyme activity by neutralizing digestive proteases released from the gut during an operation. Intestinal stress may be caused by surgery, inflammatory conditions, infections and decreased blood flow to the intestine. The formulation was also developed to help restore bowel function following an operation.

The firm’s LB1148 formulation was recently granted a new patent for its use in the treatment of post-operative ileus and adhesions. This is a major milestone for the firm, which is focused on advancing its clinical pipeline and providing more data that will support the formulation’s approval for use by patients.

Palisade Bio Inc. (PALI), closed Tuesday's trading session at $4.02, up 81.9005%, on 62,355,850 volume. The average volume for the last 3 months is 753.978M and the stock's 52-week low/high is $2.04/$134.00.

BrewBilt Manufacturing, Inc. (BBRW)

We reported earlier on BrewBilt Manufacturing, Inc. (BBRW), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

BrewBilt Manufacturing, Inc. is one of the only California companies that custom designs, hand crafts, and integrates processing, fermentation, and distillation processing systems for the craft beer, cannabis, and hemp industries. The Company uses "Best in Class" U.S. made components integrated with stainless steel processing vessels using only American made steel. BrewBilt Manufacturing’s dedication is to helping build the craft beer community one brewery at a time. Founded in 2014, BrewBilt Manufacturing is headquartered in Grass Valley, California. The Company lists on the OTC Markets.

All BrewBilt Manufacturing products are designed and fabricated as "food grade" quality. This enables the Company to manufacture vessels for food & beverage processing. BrewBilt has been making systems that are pharmaceutical grade for clients involved in distillation for the cannabis and hemp industries over the past 36 months, thus making the revenue potential considerably greater.

The Company works with its clients every step of the way. This is from concept to opening. BrewBilt helps its clients keep on track. This is from working with their bankers on financing solutions, their architect and contractor on equipment layout, to scheduling, logistics, and continuing project management.

BrewBilt provides a six-year material and workmanship warranty on everything it builds. The BrewBilt team includes brewers, design engineers, craftsmen, and owners with greater than 50 years of business experience.

BrewBilt Manufacturing, Inc. (BBRW), closed Tuesday's trading session at $0.0004, up 100%, on 753,978,186 volume. The average volume for the last 3 months is 1,901 and the stock's 52-week low/high is $0.000195/$0.30.

Natuzzi S.p.A. (NTZ)

SmarTrend Newsletters, StockMarketWatch,, StreetInsider, Street Insider, TradersPro, QualityStocks, CoolPennyStocks, HotOTC, InvestorPlace, InvestorsUnderground, MadPennyStocks, MarketBeat, BullRally, PennyStockVille, StockEgg, StockRich, The Street and PennyInvest reported earlier on Natuzzi S.p.A. (NTZ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Natuzzi S.p.A.(NYSE: NTZ) is a company involved in designing, manufacturing, marketing and selling leather and fabric upholstered furniture.

The firm has its headquarters in Santeramo in Colle, Italy and was incorporated in 1959 by Pasquale Natuzzi. Prior to its name change in June 2002, the firm was known as Industrie Natuzzi S.p.A. It operates as part of the furnishings, fixtures and appliances industry, under the consumer cyclical sector. The firm serves consumers around the globe.

The company operates through the Natuzzi brand and Softaly/Private label segments. The Natuzzi brand segment is involved in manufacturing and marketing of an extensive range of upholstered furniture that has been manufactured in production facilities located in Italy and abroad. On the other hand, the Softaly segment manufactures sofas for the mass market sold under the Softaly brand. The company derives most of its revenue from the United States.

The enterprise’s products primarily include stationary furniture such as loveseats, sofas and armchairs; home furnishing accessories like lamps, wall units, rugs and coffee tables; motion furniture; sectional furniture; sofa beds; occasional chairs, like massage chairs and recliners; and home accessories, including mirrors, vases, trays, magazine racks and decorative objects. It also sells polyurethane foam and leather by-products. As of December 2021, the firm had 326 Natuzzi Editions stores, 253 Natuzzi Italia stores, and 72 Divani & Divani by Natuzzi stores.

The firm recently announced its latest financial results, with its CEO noting that they remained focused on accelerating the firm’s transformation. This will help generate long-term value for its shareholders.

Natuzzi S.p.A. (NTZ), closed Tuesday's trading session at $5.1093, up 6.4437%, on 1,901 volume. The average volume for the last 3 months is 88,296 and the stock's 52-week low/high is $4.40/$17.00.

Icosavax Inc. (ICVX)

MarketBeat reported earlier on Icosavax Inc. (ICVX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Icosavax Inc. (NASDAQ: ICVX) is a biopharmaceutical firm that is focused on developing and commercializing vaccines against infectious illnesses.

The firm has its headquarters in Seattle, Washington and was incorporated in 2017, on November 1st by David Baker and Neil King. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers in the United States.

The company is focused on developing high impact vaccines against infectious ailments in vulnerable older adults to improve human health and address unmet medical needs. It utilizes a unique approach that uses virus-like particles (VLPs), which have intentionally been designed to mimic the structure of viruses in order to empower a better immune response.

The enterprise uses its virus-like particle platform technology to develop vaccine candidates, with a primary focus on life-threatening respiratory illnesses. Its pipeline is comprised of a vaccine candidate with hMPV target dubbed IVX-241; a vaccine candidate with RSV target dubbed IVX-121, which is in phase 1/1b clinical trials; an original receptor binding domain sequence antigen with SARS-CoV-2 target indication known as IVX-411, which is in phase 1/2 trials; and a respiratory syncytial virus monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication dubbed IVX-A12.

The company recently announced its latest financial results, with its CEO noting that they were focused on advancing their vision of developing combination vaccine candidates. This will benefit patients with various indications while also opening the company up to new growth and investment opportunities.

Icosavax Inc. (ICVX), closed Tuesday's trading session at $3.03, up 9.5841%, on 88,803 volume. The average volume for the last 3 months is 2.014M and the stock's 52-week low/high is $2.28/$29.0208.

Aurinia Pharmaceuticals (AUPH)

MarketClub Analysis, MarketBeat, Schaeffer's, TraderPower, The Street, StreetInsider, BUYINS.NET, Wall Street Resources, StockMarketWatch, InvestorPlace, Promotion Stock Secrets, Top Pros' Top Picks, Barchart,, Jason Bond, Trades Of The Day, Zacks, The Online Investor, InvestorsUnderground, Daily Trade Alert, Wealth Insider Alert and SmallCapReview reported earlier on Aurinia Pharmaceuticals (AUPH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (FRA: IKAP) (LON: 0UJF) is a commercial-stage biopharmaceutical firm that is focused on the development and commercialization of treatments for a range of illnesses with unmet medical needs.

The firm has its headquarters in Victoria, Canada and was incorporated in 1993, on June 16th by Michael Martin, Richard Glickman and Robert Foster. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers across the globe, with a focus on the United States and Canada.

The company is focused on delivering therapies to treat targeted patient populations that are impacted by severe ailments with high unmet medical needs. It is party to a collaboration and license agreement with Otsuka Pharmaceutical Company Limited. Geographically, it generates most of its revenues from the United States. The company focuses its development efforts globally.

The enterprise’s product pipeline is comprised of an investigational calcineurin inhibitor immunosuppressant drug dubbed LUPKYNIS (voclosporin), which has been developed to treat adult patients suffering from active lupus nephritis and focal segmental glomerulosclerosis. This formulation is known to improve near and long-term outcomes in lupus nephritis when used in combination with mycophenolate mofetil and steroids. The enterprise is also advancing a topical formulation dubbed voclosporin ophthalmic solution, for the treatment of dry eye syndrome.

The firm announced its latest financial results, which show increases in its revenues. It remains committed to advancing its formulations through collaborations and agreements with other pharmaceutical firms. This will positively influence its growth as well as investments into the firm.

Aurinia Pharmaceuticals (AUPH), closed Tuesday's trading session at $4.65, up 0.215517%, on 2,013,821 volume. The average volume for the last 3 months is 3.101M and the stock's 52-week low/high is $4.49/$24.55.

FOXO Technologies (FOXO)

We reported earlier on FOXO Technologies (FOXO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

FOXO Technologies Inc. (NYSE American: FOXO) is a technology platform firm that is focused on the commercialization of longevity science through services and products which serve the life insurance industry.

The firm has its headquarters in Minneapolis, Minnesota and was incorporated in 2019. It operates as part of the health information services industry, under the healthcare sector. The firm serves consumers around the globe.

The company is on a mission to empower individuals to live longer and better, own their data and control their future through advancements in human longevity optimization. Its epigenetic technology applies artificial intelligence to DNA methylation to identify molecular biomarkers of human health and aging. The company’s underwriting technology integrates saliva-based epigenetic biomarkers into accelerated underwriting protocols.

The enterprise is developing services and products which combine longevity science with life insurance to support the consumer health and wellness engagement and simplify the consumer underwriting journey. It provides a services platform dubbed FOXO Labs, which provides life insurance carriers consumer engagement and saliva-based underwriting technology services. The platform incorporates health and wellness information related to longevity science into life insurance products. The enterprise also develops an insurance products platform known as FOXO Life.

The company recently entered into an agreement with Haven Life, an insurance technology firm, through its Foxo Life subsidiary. This move will allow the company to occupy a larger market share in the industry by expanding its footprint among independent distribution channels. This will, in turn, open it up to new growth opportunities.

FOXO Technologies (FOXO), closed Tuesday's trading session at $0.72, up 47.5712%, on 3,205,479 volume. The average volume for the last 3 months is 388,108 and the stock's 52-week low/high is $0.418/$7.29.

Yatra Online (YTRA)

MarketBeat, StreetInsider, StockMarketWatch, Zacks, Schaeffer's, QualityStocks, MarketClub Analysis and Daily Market Beat reported earlier on Yatra Online (YTRA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Yatra Online Inc. (NASDAQ: YTRA) (FRA: 26Y) is an online travel firm that is engaged in the provision of online travel agency services.

The firm has its headquarters in Gurugram, India and was incorporated in 2005 by Sabina Chopra, Manish Amin and Dhruv Shringi. It operates as part of the travel services industry, under the consumer cyclical sector. The firm serves consumers in India.

The company operates through the Hotels and Packages, Air Ticketing and Others segments. The Hotels & Packages segment offers holiday packages and hotel reservations. The Ticketing segment offers facilities to book and service international and domestic air tickets to ultimate customers. On the other hand, the Others segment includes income from sale of rail and bus tickets, income from facilitating website access to travel insurance firms, income from freight forwarding services, income from the sale of coupons and vouchers, and advertisement income from hosting advertisements on its websites.

The enterprise offers travel-related services, including international and domestic air ticketing, homestays, hotel bookings, holiday packages, rail ticketing, bus ticketing, cab bookings and ancillary services for leisure and business travelers. It offers its services through mobile apps that include an application for the flight check-in process for travelers dubbed Yatra Web Check-In; a self-booking application for business customers known as Yatra Corporate; and a mobile interface dubbed Yatra.

The firm, which recently announced its latest financial results, recently attained its plan to launch its IPO before the year’s end. This move not only allows the firm to expand and invest in technology but also bolster its growth, which will be good for its shareholders.

Yatra Online (YTRA), closed Tuesday's trading session at $2.79, off by 2.7875%, on 388,108 volume. The average volume for the last 3 months is 1.094M and the stock's 52-week low/high is $1.32/$3.00.

atai Life Sciences N.V. (ATAI)

MarketBeat, The Online Investor, QualityStocks, StockMarketWatch, StreetInsider, Dynamic Wealth Report, Uncommon Wisdom,, MarketClub Analysis, CRWEFinance, CRWEPicks, CRWEWallStreet, DrStockPick, PennyOmega, BestOtc, PennyToBuck, StockHotTips, TraderPower, StockOodles, Street Insider, The Street, TopPennyStockMovers and Schaeffer's reported earlier on atai Life Sciences N.V. (ATAI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The current wave of surging psychedelic research and mainstream popularity has been dubbed the psychedelic renaissance. Decades after they were prohibited, hallucinogenic drugs are revealing astonishing mental-health benefits in clinical trials.

Research has shown that even a single dose of psychedelics can have long-term benefits against mental-health issues such as depression and eating disorders when paired with psychotherapy.

With people becoming more cognizant of the side effects of traditional psychiatric medications, many individuals are looking at psychedelic-assisted therapy as a safer and more effective alternative. The industry is still in its infancy, however, and the direction it will take if the federal government and states pass legislation allowing psychedelic use is still unknown.

According to Gwella Mushrooms CEO Peter Reitano, the psychedelics market will be dominated by the wellness segment rather than pharmaceutical applications. His point of view is quite unique as a majority of companies in the nascent psychedelic space are looking to develop psychedelic therapies for pharmaceutical applications.

Based in Canada, Reitano’s psychedelics company is hedging its bets on the wellness market becoming the most dominant sector in the psychedelics industry. Reitano believes that as the industry grows, the most significant application for psychedelic drugs will be as supplements meant to improve your well-being rather than medications meant to alleviate medical conditions.

At the moment, Reitano said that there is a thin line in regard to what regulators allow, what psychedelics can do, and what the public is willing to accept when it comes to treating people with psychedelics. His company is looking to corner the wellness segment with low-dose psychedelics taken as supplements.

Gwella’s Mojo Microdose Gummies boost wellness by improving oxygen levels, boosting the immune system, promoting calm and clarity, and increasing energy. Reitano described microdosing as consuming a “low, subperceptual dose” of a hallucinogenic drug to get the benefits without having to go through the psychedelic experience.

He explained that Gwella is developing ways to help people improve their lives through a variety of facets, be it cognitive enhancement, wellness or creativity. As such, the psychedelics company has developed products that are additive to one’s life and enhance their wellness.

Furthermore, the company has been able to avoid the restrictions placed on the pharmaceutical markets, and its products can be purchased online in Canada, Europe and the United States. Reitano said that Gwella’s psychedelic micro dose products have been in the market for a year and have generated more than $1 million in revenue.

Gwella can focus on the wellness front while others, such as atai Life Sciences N.V. (NASDAQ: ATAI) explore the pharmaceutical angle. All efforts will ultimately converge with regards to advancing the psychedelics industry.

atai Life Sciences N.V. (ATAI), closed Tuesday's trading session at $2.92, up 1.7422%, on 1,093,708 volume. The average volume for the last 3 months is 410,245 and the stock's 52-week low/high is $2.60/$12.27.

Alliance Resource Partners L.P. (ARLP)

The Online Investor, Zacks, TradersPro, QualityStocks, The Street, MarketBeat, InvestorPlace,, MarketClub Analysis, TopStockAnalysts, Dividend Opportunities, The Wealth Report, TheStockAdvisor, The Motley Fool, Money Morning, StreetAuthority Daily, Market Intelligence Center Alert, BUYINS.NET, Investing Daily, Daily Wealth, Daily Trade Alert, Rick Saddler, TraderPower, SmarTrend Newsletters, The Growth Stock Wire, Wealth Insider Alert, TheOptionSpecialist, TheStockAdvisors, Trading Concepts, Daily Markets, Trades Of The Day, Eagle Financial Publications, Early Bird, FNNO Newsletters, Greenbackers, Insider Wealth Alert,, Investor Update, Short Term Wealth, Top Pros' Top Picks, Leeb's Market Forecast, TheTradingReport, TheStreet Offers, Money and Markets, StreetInsider and Investment U reported earlier on Alliance Resource Partners L.P. (ARLP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Like several other European Union countries, Germany is turning back to coal to generate power as the winter fast approaches. Before Russia invaded Ukraine, Germany and several other countries across the EU had been working to shut down their coal-fired power plants in favor of greener options such as solar and wind power. However, Germany is now actively working to build its coal stockpiles as the global energy crunch gets worse amid worsening economic conditions and a fast-approaching winter.

The Russian-Ukraine war has led to one of the worst energy crises in Europe and the world at large in decades. Soon after the Kremlin invaded Ukraine, several Western countries issued sanctions against Russia to slow its economy and harm its war effort in Ukraine.

The fallout from these sanctions has been devastating; Russia cut gas supplies to the rest of Europe, inevitably leading to an energy supply crunch that forced European countries such as Germany to go back to the drawing board and re-examine their energy mix.

In the industrial area of North Rhine-Westphalia, German utility Marl Chemical Park is slated to keep running throughout the winter. The power plant was scheduled to shut down by the end of 2022 but will continue running instead, maintaining more than 10,000 jobs and generating energy for companies on the site.

The extension of Marl Chemical Park’s life is a clear indication of the energy crunch that has gripped Germany in its clutches for the past couple of months.

Other governments and companies across Europe are hastening to develop contingency measures to ensure their grids continue supplying power to citizens over the cold winter.

Although coal is among the dirtiest fuels on the planet, it is in abundance, and plenty of European countries already have the infrastructure needed to generate power via coal. Germany’s strategy has been to halt the shutdowns of several coal-fired power plants and extend the lives of the facilities.

Germany has also opted to keep three of its remaining nuclear power plants operational until mid-April next year. These nuclear plants were slated to close by the end of the year but will be allowed to keep running for a few more months to supply extra energy to Germany’s grid over the coming cold months.

With winter almost upon us, European countries are scrambling to find an alternative to the cheap Russian gas that powered their grids for years. Harold Schwager, the deputy chair of German specialty company Evonik, noted that the ongoing power crisis is very acute and that the solution to the problem would be to increase energy supplies and reduce prices.

All this demand for coal at this time is creating a massive market for coal-extraction companies around the world, such as Alliance Resource Partners L.P. (NASDAQ: ARLP).

Alliance Resource Partners L.P. (ARLP), closed Tuesday's trading session at $22.66, up 1.2059%, on 410,245 volume. The average volume for the last 3 months is 22.97M and the stock's 52-week low/high is $9.66/$27.63.

Lucid Motors (LCID)

Green Car Stocks, InvestorPlace, Schaeffer's, MarketClub Analysis, The Street, QualityStocks, MarketBeat, StocksEarning, Trades Of The Day, Daily Trade Alert, Kiplinger Today, The Online Investor, Early Bird, Investopedia, The Wealth Report and Louis Navellier reported earlier on Lucid Motors (LCID), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

There should be a far less expensive battery to support an electric vehicle that is cost effective. In this regard, a number of auto manufacturers are planning to adopt Lithium-iron-phosphate batteries, also referred to as LFP, a battery that China uses largely and whose battery cells are less expensive than those made of nickel and cobalt.

Ford Motor Co. and other EV manufacturers, including Tesla, agree that the use of lithium iron phosphate batteries, which have a lower energy density, might actually reduce the cost of EVs by avoiding the use of nickel and cobalt, which are expensive and in short supply. International EV manufacturers are making plans on how to make these batteries available as they continue to inject more billions to increase the number of electric vehicles on the market. To this end, they are making short-term plans while keeping an eye on the mineral price changes, the technological advancement of batteries and governmental regulations as they put the EV sector to test.

For example, after the rise in cobalt and nickel prices and a disruption in their chain of supply that slowed their production in the previous year, Rivian Automotive Inc. is switching to LFP cells in some of its EVs, including its trucks. CEO RJ Scaringe said that the company has high hopes for LFP, mentioning that the cell performed admirably well when the vehicle required frequent charging.

Initially, LFP in China would mostly be used for inexpensive short-distance vehicles. In Europe, the highly priced cobalt and nickel has been preferred due to their longer range, but this has since changed, said auto executives. The largest supplier of nickel was affected by the Ukraine war, which led to soaring nickel prices; cobalt prices have also doubled in the latest years, and manufacturers have decided to use less of the mineral while responding to environmental and human rights violations in cobalt mining in the Congo where cobalt is largely sourced. Thus, LFP-iron-based cells continue to be important and remain a strong factor in the industry’s evolution.

The iron-based battery cell is also supported by analysts for having a low fire risk and because its properly contained within the car, thus increasing the mileage. Likewise, this chemistry also assists automakers to broaden their battery supplier base in the event of a limited supply.

One researcher expects more than 40% of electric vehicles to be equipped with LFP batteries as we approach 2030. He added that LFP use should not be underestimated because it will eventually spread worldwide and most likely be featured in future models from all types automakers, including Lucid Motors (NASDAQ: LCID).

Lucid Motors (LCID), closed Tuesday's trading session at $10.13, off by 1.7459%, on 23,082,776 volume. The average volume for the last 3 months is - and the stock's 52-week low/high is $9.98/$57.44.

The QualityStocks Company Corner

Cub Crafters Inc.

The QualityStocks Daily Newsletter would like to spotlight Cub Crafters Inc.

CubCrafters, the leading designer and manufacturer of light-sport,experimental and Part 23 certified backcountry aircraft, wasfeatured in a recent article published by Kitplanes Magazine. The piece discusses qualification of CubCrafters by theSecurities Exchange Commission (“SEC”) to make a $50 million publicstock offering using the Regulation A+ exemption. This allows forthe first outside investment ever in the history of the iconic company. “We have invested largeamounts of time, energy and resources to qualify a Reg A+ offeringwith the SEC,” Brad Damm, CubCrafters’ vice president, was quotedin the article. “Our brand has grown to be synonymous with anadventure lifestyle that inspires and appeals to people at alllevels. We consistently hear from people across many differentdemographics that want to be a part of what we do, that want tojoin us on our journey. This offering affords that opportunity toeveryone, both from within the aviation community and from thepublic at large.” In addition, CubCrafters was featured in the Bell2Bell Podcast, a part of IBN’s (“InvestorBrandNetwork”) sustained effort to provide specializedcontent distribution via widespread syndication channels. PatrickHorgan, the company’s president and CEO, joined the latest episode to provide an introduction to CubCrafters, discuss the company’sbest-in-class backcountry aircraft, and share a preview of anexciting future as the company raises capital for its expansion tokeep up with demand in the backcountry aircraft market segment.“Increasing manufacturing to reduce our order back log is key. Wehave plans to expand internationally, and one of the other keyfocuses for the use of proceeds is improving our services andsupport structure,” Horgan said. “CubCrafters is the preeminentbuilder of adventure airplanes. We build advanced versions of theSuper Cub using current-day technology. It’s a utilitarian-typeairplane that can access backcountry areas without the need forrunways. It’s high performance, with the latest technology, enginesand avionics. It’s an airplane that can be used commercially, aswell as just for a lot of fun.” To view the full article and pressrelease, visit and

Cub Crafters Inc. (typically styled CubCrafters) is an OEM aircraft manufacturer based at McAllister Field Airport in Yakima, Washington. The company was founded in 1980 to build parts and supplementary type certificate (STC) improvement modifications, which were used to establish it as the preeminent center for rebuilding the classic Piper PA-18 Super Cub light aircraft. CubCrafters went on to advance the market with its own, newly manufactured aircraft models and holds an approved Federal Aviation Administration (FAA) Production Certificate. Yakima-based operations include an engineering design-test-certification center, aircraft parts and assembly production facilities, and an MRO maintenance service and overhaul facility.

The first newly manufactured aircraft by the company, the CC18-180 Top Cub, was Federal Aviation Administration (FAA) type certified in December 2004. The Top Cub was also granted type certificates (TC) by Transport Canada in July 2008, followed by Australian certification in August of that same year. With the FAA’s release of the new Light Sport Aircraft (LSA) class, CubCrafters created a brand-new model in 2008, the CC11-100 Sport Cub, similarly based on the original Piper J-3 Cub’s appearance, which it validated to ASTM international standards as an LSA. This model advanced to become known as the Carbon Cub, the bestselling LSA of all time in the U.S.

CubCrafters focuses on four main product lines, including the Carbon Cub SS, Carbon Cub FX, XCub, and the Top Cub under license. Some models are built to be lightweight and powerful for quicker flights, while others are built for longer missions in unforgiving backcountry environments.

CubCrafters has a service and overhaul facility for PA-18 Super Cubs and other Cub derivative designs at its Yakima headquarters. The company sells aircraft kits as well as finished aircraft.


The Carbon Cub is available in three variants: Carbon Cub SS (production Light Sport Aircraft), Carbon Cub FX (an innovative Builder Assist E/A-B aircraft) and Carbon Cub EX (E/A-B aircraft kit). Carbon Cub has been designed for off-airport operation with a powerful engine, strong lightweight airframe and nimble low-speed manners. The Carbon Cub has taken the fundamentally superior design of the Piper Super Cub and reinvented it using 21st century materials and computer-aided design. Superior engineering results include the Carbon Cub having 50% fewer parts and weighing more than 300 pounds less than a similarly equipped Super Cub. Now in its third generation of innovation advancements, there are over 1,000 Carbon Cubs flying.

The CubCrafters CC19-180 XCub, FAA Certified and introduced in June 2016, is supplied complete and ready-to-fly. The XCub is a further scaled development of the CubCrafters Carbon Cub, which the company continues to supply, but with higher performance and incorporating more structural carbon fiber. The XCub was developed over a six-year period and not publicly announced until FAA TC had been completed and issued. The process was completed organically using company resources and did not involve any venture capital, loans nor any advanced customer deposits. XCub is built on a wholly original fuselage design. The CNC-milled 4130 chromoly steel frame meets the latest FAA Part 23 certification standards for 2,300-pound gross weight aircraft. XCub’s useful load is as high as 1,084 pounds. Current Part 23 certification requirements ensure this is the strongest Cub ever produced. It can fly farther, providing greater comfort. It is an airplane that has taken the best from the past and, using the very latest in design, material and manufacturing technology, has established a new standard.

The XCub was approved by the FAA for seaplane operations in December 2017. That same month, EASA approved the XCub design and issued a new type certificate. Four international type certificates have been gained: EASA Dec-2017, Canada Feb-2018, Japan April-2018, and Australia Aug-2018.

CubCrafters increased the horsepower of the XCub line in 2019, offering two new models: the CC19-215 FAA Certified version and the CCX-2300 Builder Assist, both powered by the new CC393i 215 HP engine built by Lycoming.

In December 2021, CubCrafters gained FAA Certification of a new nose wheel version of the XCub, branded the NXCub.

Market Overview

According to a 2022 analysis by research firm Expert Market Research (“EMR”), the global ultralight and light aircraft market was valued at $7.63 billion in 2021. The EMR report says the market is expected to grow at a CAGR of 4.5% in the forecast period of 2022-2027 to reach a value of $9.93 billion. Ultralight and light aircraft are small aircraft with on-board pilot (and perhaps passengers) designed for use in recreation, sports, pilot training, aerial surveys, mapping, research and agriculture, humanitarian backcountry access, and special military missions, as well as business and personal travel.

CubCrafters currently enjoys a dominant market share of the rugged adventure airplane market.

Management Team

Patrick Horgan is President and CEO at CubCrafters. Before he assumed that role, he was the company’s Vice President/Director of Engineering & Product Development for three years, when he led the FAA Part 23 type certificate approval and production certificate approval of CubCrafters’ newest flagship, the XCub. Mr. Horgan also directed the breakthrough certification that authorized the use of experimental avionics in FAA-certified production aircraft, a first in aviation history. He brings over 30 years’ aircraft development and manufacturing experience in general aviation, commercial, and military industries. Prior to service at the company, he was the General Manager at WACO Classic Aircraft Corporation in Battle Creek, Michigan, and was the commercial aircraft manager of the Boeing 777 wheel and brake program for Goodrich Aerospace in Troy, Ohio. He was also a designer on the F/A-18 Super Hornet at McDonnell Douglas (now Boeing) in St. Louis, Missouri. Mr. Horgan holds degrees in aeronautical and astronautical engineering from the University of Illinois, and a certificate in Disruptive Strategy from Harvard Business School. He serves as a member of the Board of Directors of the General Aviation Manufacturers Association and on ASTM aircraft standards committees.

Brad Damm is Vice President at CubCrafters. He has overseen CubCrafters’ sales, marketing, and brand management operations since 2018. Since first joining CubCrafters in 2013, Mr. Damm has served as Factory Direct Sales Manager, the Director of Sales Support, the Global Director of Sales, and the Vice President of Sales and Marketing. During his tenure, the company has seen new sales records year after year across all of CubCrafters new aircraft and kit product lines, and the CubCrafters brand has risen to new levels of awareness and respect with aviation consumers worldwide. Prior to joining the company, he served for over 10 years as the Business Development Manager for one of the largest commercial concrete contractors in the Pacific Northwest, driving the sales and revenue growth that allowed the company to expand from a few dozen to hundreds of employees.

Rick Johnson is the Director of Finance at CubCrafters and has been with the company since 2017. He has 27 years of previous experience as controller and CFO for fruit packing and timber operations in the Pacific Northwest. He holds a Bachelor of Science in Business Administration from Central Washington University.

Christopher Matus is Production Manager at CubCrafters and joined the company in 2011. Before taking that post, he held positions as Fabrication Plant Manager, Machine Shop Manager and CNC Machinist for the company. He has also served as a Combat Engineer in the Washington Army National Guard, deploying to Afghanistan and to natural disasters including the 2014 Oso Mudslide.

Justin Jansky is the Administrative Manager at CubCrafters. He joined the company in 2015 and has a demonstrated history of successful collaboration on major FAA type certification projects in the general aviation industry, specifically under 14 CFR Parts 21 and 23. He is responsible for process management, document control, facilitating FAA certification processes, coordination with FAA delegates and documenting compliance testing. He holds a bachelor’s degree in technology and applied design.

Recent News


InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development andmanufacturing of rare cannabinoids and cannabinoid analogs, hasclosed on a private placement with two healthcare-focusedinstitutional investors. The placement included the sale of1,818,185 INM common shares, which were issued at a purchase priceof $3.30 per share (or prefunded warrant in lieu thereof); theshares were priced at-the-market under NASDAQ rules. Theannouncement also noted that InMed issued unregistered preferredinvestment options to the investors in the offering to purchase upto 3,272,733 common shares. The offering resulted in approximately$6 million in gross proceeds for the company, which plans to usethe funds to continue pipeline development of its pharmaceuticaldrug candidates as well as advance manufacturing know-how ofcannabinoids and cannabinoid analogs; the company may also useportions of the proceeds to support intellectual propertydevelopment and other commercial activities and for general workingcapital purposes. According to the announcement, H.C. Wainwright& Co. acted as the exclusive placement agent for the offering.To view the full press release, visit

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.


The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Tuesday's trading session at $2.72, up 5.0193%, on 489,338 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $N/A/$.

Recent News

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF)

The QualityStocks Daily Newsletter would like to spotlight Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF).

Eloro Resources (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) today announced its entry into an option agreement to acquire theMina Casiterita and Mina Hoyada properties, which collectivelycover 14.75 km southwest and west of the Iska Iska Silver-TinPolymetallic Project. According to the update, artisanal mining inthe 1960s identified high-grade tin veins on the Mina Casiteritaproperty that are hosted in intrusive dacite. From 1962 to 1964,the Departamento Nacional de Geología (National Department ofGeology) reported production in Bolivia as 69.85 tonnes grading50.60% Sn. The company has also staked additional claims in theIska Iska region. Following the acquisition, Eloro will control theland package collectively totaling 1,935 quadrants covering 483.75km. “These properties will add significantly to our land positionat Iska Iska and provide an excellent opportunity to test thepotential for a major tin deposit with much shallower diamonddrilling than on the main Iska Iska discovery,” said Tom Larsen,CEO of Eloro. “Geological mapping and sampling is in progress onthese new properties as well as magnetic surveys. Immediatelyfollowing the completion of its acquisition, we plan to drill testmajor targets on the Mina Casiterita property.” To view the fullpress release, visit

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) is a publicly traded exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec.

The company has an option to acquire a 99% interest in the highly prospective Iska Iska Property, classified as a silver-tin polymetallic epithermal-porphyry complex, a significant mineral deposit type in the Potosi Department of southern Bolivia. Iska Iska is a road-accessible, royalty-free property.

Eloro also owns an 82% interest in the La Victoria Gold/Silver Project, located in the North-Central Mineral Belt of Peru, some 50 kilometers south of Barrick’s Lagunas Norte Gold Mine and Pan American Silver’s La Arena Gold Mine. La Victoria consists of eight mining concessions and eight mining claims encompassing approximately 89 square kilometers. La Victoria has good infrastructure, with access to road, water and electricity, and is located at an altitude that ranges from 3,150 meters to 4,400 meters above sea level.

The company has a strong management and technical team working diligently to uncover the value of both Iska Iska and La Victoria. Eloro is based in Toronto, Canada.


Iska Iska – Potosi, Bolivia

Iska Iska is associated with a Miocene possibly collapsed/resurgent caldera, emplaced on Ordovician age rocks with major breccia pipes, dacitic domes and hydrothermal breccias. The property is wholly controlled by the title holder, Empresa Minera Villegas S.R.L. It is located 48 kilometers north of Tupiza city, in the Sud Chichas Province of the Department of Potosi. This is an important mineral deposit type in the prolific South Mineral Belt of Bolivia. Eloro commissioned a NI 43-101 Technical Report on Iska Iska, which was completed by Micon International Limited and is available on Eloro’s website and under its filings on SEDAR.

A fully financed drill program is currently underway on the property, situated near world-class deposits including Silver Sand, San Bartolomé, Pulacayo, San Cristobal, San Vicente, Chorolque, Tasna, Choroma and Siete Suyos. Iska Iska is in the southwest part of the Eastern Cordillera, which hosts a number of major polymetallic mines and mineral deposits. Drilling and continuous channel sampling results have demonstrated some very high metal values, especially silver and tin, within an immense system, where mineralization has been encountered in every drill hole to date. The company believes there is excellent potential for world-class bulk mineable deposits.

La Victoria – Ancash, Peru

The La Victoria project, targeting gold and silver production, is situated near world-class, low-cost gold producers Pan American Silver and Barrick Gold Corporation. Located in Ancash Department, La Victoria sits on the western slopes of the Peruvian Andes. The property is located 12 hours from Lima, with a travel distance of 600 kilometers. The nearest road accessible population centers from La Victoria are Huandoval, Pallasca and Cabana. The project includes four principal mineralized zones in Peru’s prolific North-Central Mineral Belt – San Markito, Victoria, Victoria South and Ccori Orcco – with excellent potential for gold discovery. Operations at La Victoria are planned to proceed with a 2,000-meter diamond drilling program to test targets to outline potential resources at San Markito. Trenching and sampling confirmed high silver values and veins at San Markito in 2020.

Market Outlook

According to industry association The Silver Institute, the outlook for silver demand is exceptionally promising, with global demand forecast to rise to a record high of 1.112 billion ounces in 2022. The increase will be driven by record silver industrial fabrication, which is forecast to improve by 5%, as silver’s use expands primarily in solar energy and electric vehicle (EV) manufacturing. The institute states that government commitments to carbon neutrality have resulted in a rapid expansion of green energy projects, driving record photovoltaic panel installations which are expected to lift silver demand in this segment to an all-time high in 2022.

Rising demand in the electronics industry is also boosting the demand for tin, which is primarily used in solder. The electronics and electrical industries use solders containing 40-70% tin, which provide strong and reliable joints under a variety of environmental conditions. At present, the majority of the assemblers are using patented tin-and-copper-based solders. Mordor Intelligence estimated tin demand at 387 kilotons in 2021 and forecasts demand growth of 2.5% annually through 2027. Over the medium term, surging demand from the EV market and increasing applications in the electrical and electronics industry is expected to drive the market.

Management Team

Thomas G. Larsen is CEO of Eloro. He has more than 40 years of experience in the investment industry, specializing in corporate finance and management of junior resource companies, raising in excess of C$200 million. He previously held the position of President and Chief Executive Officer of Champion Iron Limited. Prior to that, he was President and Chief Executive Officer of Champion Iron Mines Limited.

Dr. Bill Pearson is Executive VP of Exploration for Eloro. He has more than 40 years of direct experience in the exploration and production of minerals worldwide. He played an integral role in the acquisitions of Desert Sun Mining Corp. by Yamana Gold in 2006 and Central Sun Mining by B2 Gold in 2009. He was formerly VP Exploration at Desert Sun Mining and Senior VP at Central Sun Mining.

Miles Nagamatsu, CPA, is CFO at Eloro. He has over 30 years of experience in accounting, management, lending, restructurings and turnarounds. Since 1993, he has acted as a CFO of public and private companies primarily in the mineral exploration and investment management sectors. He holds a Bachelor of Commerce degree from McMaster University.

Osvaldo Arce Burgoa is General Manager at Eloro. He is a geological and mineral processing engineer with 26 years of experience in Bolivia. He is a former President of the Bolivian Geological Society, Main Technical Advisor of the National Mining Corporation (COMIBOL) and has served as exploration manager and chief geologist at various mining and exploration companies. He has authored two books on Bolivian geology and holds a doctorate in mining engineering from Tohoku University in Sendai, Japan.

Eloro Resources Ltd. (OTCQX: ELRRF), closed Tuesday's trading session at $2.31, up 4.5249%, on 25,902 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.09/$4.46.

Recent News

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

The QualityStocks Daily Newsletter would like to spotlight BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

BiondVax summarizes collaboration with the prestigious Max PlanckInstitute for Multidisciplinary Sciences and the University MedicalCenter Göttingen to discover and develop nanosized antibody(NanoAb) therapies that address underserved and growing markets,including COVID-19, psoriasis, asthma, psoriatic arthritis and wetmacular degeneration.

The global COVID-19 therapy market was valued at $16.8 billion in2021 and is expected to grow at a CAGR of 20% during the forecastperiod, resulting in a value of $35.42 billion by 2025

The psoriasis market is experiencing a higher-than-expected demandacross all regions due to the increasing geriatric population andthe growing prevalence of plaque psoriasis and psoriatic arthritisresulting in an anticipated value of $47.24 billion by 2029

Joshua E. Phillipson, BiondVax Pharmaceuticals (NASDAQ: BVXV) Director of Communications and Investor Relations, recentlypresented the company’s corporate presentation to investorsattending the LD Micro Main Event hosted by SRAX, Inc. at the Luxein Los Angeles and online via Sequire Virtual Events platformOctober 25-27, 2022. The LD Micro Main Event, known as the“Woodstock” of the micro-cap world, has been showcasing the nextbig names in the space for the last 15 years. Phillipson wasprovided with 25 minutes on the main stage to offer investors anin-depth look at the company. The video is available at (free registration required).

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), closed Tuesday's trading session at $0.9222, up 5.082%, on 47,344 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.5335/$3.49.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

The National Brain Tumor Society anticipates that more than 13,000Americans will receive a GBM diagnosis during 2022, accounting for49.1% of all primary malignant brain tumors

CNS announced the first patient in Europe has been enrolled anddosed in the global trial to evaluate Berubicin for the treatmentof GBM

Berubicin is a novel anthracycline and the first to appear to crossthe blood-brain barrier

The global GBM treatment market is expected to reach a value of$4.2 billion by 2028, driven by the increased approval granted bythe FDA for novel GBM treatment therapies

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company specializing in thedevelopment of novel treatments, announced that the first patientin Europe has been enrolled and dosed in France in the company'songoing potentially pivotal global trial to evaluate Berubicin forthe treatment of recurrent glioblastoma multiforme (“GBM”), anaggressive and incurable form of brain cancer. According to theNational Brain Tumor Society, more than 13,000 Americans areexpected to receive a GBM diagnosis during 2022, which accounts for49.1% of all primary malignant brain tumors (

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Tuesday's trading session at $0.21, up 1.4493%, on 74,360 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.16/$1.38.

Recent News

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

Ammonia is a highly efficient carrier of both hydrogen andnitrogen, with nitrogen being a critical component to fertilizersand world food production, but traditional ammonia productionresults in large greenhouse gas emissions

FuelPositive’s carbon-free “green ammonia” production technologyrepresents an environmentally superior way of producing ammonia

The company’s confidence in its product has seen it go the extramile to develop on-farm containerized, green ammonia productionsystems, that can be leveraged on a smaller scale to create greenammonia for agricultural fertilizers on-site

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a company focused on licensing, partnership, and acquisitionopportunities related to energy-efficient, climate-safe, andsustainable solutions and sustainability, recognizes the rapidlygrowing demand for green technologies. The need is formalized inthe UN’s 2050 Net Zero Goal for the drastic reduction of greenhousegas emissions ( While there is a warranted push towards solar and wind energy,the company is bringing something new and viable to the discussion:green ammonia.

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

  • Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
  • Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
  • End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Tuesday's trading session at $0.114, up 1.1984%, on 359,306 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0789/$0.196.

Recent News

REZYFi, Inc.

The QualityStocks Daily Newsletter would like to spotlight REZYFi, Inc.

  • REZYFi is a Miami, Florida-headquartered growth mortgageorigination and specialized financing company that primarilytargets licensed and permitted cannabis companies and owners ofreal estate who lease to cannabis companies
  • Traditional banks are governed by federal law, whichcriminalizes marijuana; as a result, they are hesitant to offerfinancial services to cannabis businesses
  • The President recently set a process in motion that couldculminate in the rescheduling of marijuana, although given thatthis review will not actually decriminalize the substance, thestatus quo, which disadvantages cannabis companies, will remain
  • REZYFi believes cannabis-related companies will continue toexperience difficulties accessing financing from traditionalbanks, presenting a major opportunity

Last month, the President called for marijuana rescheduling bydirecting the Secretary of Health and Human Services and theAttorney General to “initiate the administrative process to reviewexpeditiously how marijuana is scheduled under federal law” ( REZYFi believes the demand for innovative financing offerings byplayers in the cannabis market will continue to grow as moregeographic markets legalize recreational and medical cannabisusage, a belief that has fueled its expansion within the UnitedStates. Currently, REZYFi is licensed in 36 states but is lookingto expand into additional jurisdictions. For more information,visit the company’s website at www.REZYFi.comDuring a recent radio appearance, incoming Minnesota governor TimWalz suggested that state lawmakers could pass a recreationalcannabis measure in the next legislative session. The Democrat saidduring the Friday morning show on WCCO that cannabis in Minnesota could finally happen in 2023. SenateDemocrats have not stated outright that they will advance cannabislegalization, but they have majority numbers and will be able to goaround any pushback offered by GOP senators. On the other hand,House Democrats seem to be ready to approve marijuana legalizationin the state if the matter lands on the floor. In more maturecannabis markets, entities such as REZYFi Inc. are helping licensed cannabis companies obtain the financing theyneed to expand, develop new products and generally contribute tothe communities they serve.

REZYFi, Inc. is a cannabis mortgage bank servicing the needs of both traditional and non-traditional consumers and businesses. Its target markets include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financings, such as solar installations and real estate development projects.

Headquartered in Miami, Florida, REZYFi operates through two wholly owned subsidiaries – REZYFi Lending, which primarily addresses emerging real estate-related financing opportunities, and ResMac Inc., the company’s traditional mortgage origination, correspondent and servicing operation. REZYFi is currently licensed in 34 U.S. states, with plans to expand to all remaining states later this year.

REZYFi is positioned as one of first cannabis mortgage bankers in the U.S., while most traditional lenders are still reticent to serve the state-licensed cannabis industry.


REZYFi Lending

REZYFi Lending leverages a wide network to offer options such as 15- and 30-year fixed-rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans and adjustable-rate mortgages.

Looking ahead, the company expects increased funding in marketing and loan agents to drive significant origination growth over the next two years, further supported by the planned launch of a high-margin cannabis division later this year.

ResMac Inc.

ResMac has been in operation for 13 years, having closed more than 20,000 loans for more than 15,000 clients. The company expects to accumulate $285 million in retail origination in 2023, alongside $250 million in wholesale origination for the same period. ResMac is further targeting $600 million in origination through its mortgage correspondent operations for 2023.

Through its ResMac subsidiary, REZYFi operates as a direct lender and originator of residential mortgages, with active mortgage correspondent and mortgage servicing operations. Through its correspondent segment, ResMac primarily purchases and aggregates residential mortgages from trusted third-party originators.

The company intends to harvest the database of customers within its mortgage servicing operations as an essential source of additional growth, especially relative to the new alternative residential loan programs being offered.

Corporate Strengths

  • Experience – REZYFi is led by a seasoned management team with significant expertise spanning a wide range of real estate and financing subsectors. The team also has extensive experience in the cannabis and hemp marketplace, which the company intends to leverage as it navigates the changing landscape of the cannabis industry while sourcing the best opportunities in the sector.
  • Network of Independent Brokers – Over the past five years, REZYFi has developed an extensive network of independent mortgage-related brokers and licensed loan officers. The company is currently training the network members on its new service offerings, with many already launching sales efforts. REZYFi believes this network will be a vital asset moving forward as other firms in the sector terminate relationships in the face of slowing mortgage business in a rising interest rate environment.
  • Proprietary Technology – REZYFi has invested heavily in designing, building and implementing proprietary automated/machine learning technology to shorten loan processing timeframes and increase efficiencies, allowing it to operate its legacy business at staffing levels meaningfully below those of its competitors.

Market Overview

REZYFi’s diversified approach to the real estate lending sector positions it to capitalize on growth in multiple verticals in the years to come.

In the first quarter of 2022, lenders issued 2.71 million residential loans, with the average balance for a first mortgage climbing to a record high of $298,324 in 2021, according to the Mortgage Bankers Association. This trend is expected to continue, with Freddie Mac forecasting a 10.4 percent increase in home prices in 2022 and a 5.0 percent bump in 2023. Growth prospects in the cannabis industry paint a similar picture.

The National Association of Realtors® issued a report in April 2021 examining the correlation between cannabis legalization and real estate demand. In states where prescription and recreational cannabis use is legal, more than a third of surveyed agents reported an increase in demand for warehouses. Likewise, 23 percent of those surveyed reported an increase in demand for storefronts, and 28 percent observed increased demand for land. As other states look to join the 19 that have embraced full cannabis legalization, this rising demand could create an opportunity for REZYFi’s cannabis-focused initiatives.

In total, an analysis by market research firm Business Research Insights projects the global loan servicing market to reach a value of nearly $1.5 billion by 2028, up from $680.8 million in 2021. Those figures represent a CAGR of 11.0 percent during the forecast period of 2022-2028.

Management Team

John Vu, Esq., is CEO of REZYFi, Inc. He has more than two decades of experience in the mortgage and commercial banking industry. He has filled many senior and executive management positions in high-producing mortgage banks, including C-level assignments. He has also served as general counsel for a nationally associated commercial bank. Mr. Vu brings considerable cannabis industry expertise to REZYFi. He has served as a corporate attorney to multiple cannabis cultivators, manufacturers and retailers.

Ji Ji Zhang, Esq., is CFO of REZYFi, Inc. He is a multifaceted entrepreneur who owns a law firm, a portfolio of hotels and a high-producing mortgage bank. Mr. Zhang is also an investor in the development of a cannabis business park. He brings more than five years of experience in mortgage banking to REZYFi, having developed Freddie Mac and HUD licenses and amassed a managed portfolio valued at over $300 million.

Kevin Heckemeyer is President of REZYFi, Inc. He has more than 25 years of experience in mortgage banking. He has built and sold several high producing mortgage businesses. In his current roles with ResMac, he is responsible for production and operations.

Spencer Dang is Chief Credit Officer of REZYFi, Inc. He has more than a decade of experience in mortgage operations. He is a direct endorsement underwriter for HUD and has specialized in non-QM underwriting. Under his watch as an underwriter, he has never had a single repurchase.

Recent News


SideChannel Inc. (OTCQB: SDCH)

The QualityStocks Daily Newsletter would like to spotlight SideChannel Inc. (OTCQB: SDCH).

SideChannel recently released Enclave, its first software product

The company acquired SideChannel in July 2022 and changed its namepost-acquisition

An industry benchmark study puts average CISO compensation at$463,000 annually, making SideChannel’s vCISO model attractive toits SMB target market

According to IBM, the average cost to organizations of acybersecurity breach is $4.2 million

Cybersecurity Ventures reports a lack of trained professionals willleave 3.5 million cybersecurity positions unfilled by 2025,increasing demand for virtual security services

SideChannel (OTCQB: SDCH) simplifies cybersecurity for mid-market companies by matching themwith highly experienced information security officers at a costlower than building an in-house information security team or hiringa full-time CISO.

SideChannel Inc. (OTCQB: SDCH) simplifies cybersecurity for mid-market companies by matching them with highly experienced information security officers at a cost lower than building an in-house information security team or hiring a full-time CISO.

SideChannel’s team of virtual Chief Information Security Officers (vCISOs) possesses a combined 400-plus years of experience in cybersecurity. They’ve honed their skills and abilities in places like Anthem, Dick’s Sporting Goods, Best Buy, TD Bank and the Pentagon. SideChannel lends this talent to clients, creating value in the form of a bespoke cybersecurity program perfectly sized for the growing enterprise.

SideChannel is committed to creating top-tier cybersecurity programs for SMBs to help them protect their data and assets. To date, SideChannel has created more than 50 multi-layered cybersecurity programs for its clients.


Reports show that cyberattacks on SMBs have increased in recent years, as organizations’ network attack surfaces have grown exponentially with remote and in-office workers increasingly relying on cloud environments, mobile devices, software applications and third-party suppliers to conduct business.

SideChannel continues expanding its service offerings, workforce and customer base, attracting over 20 virtual CISOs to serve across industries including fintech, biotech, healthcare, manufacturing, legal, defense and technology services. The company is based in Worcester, Massachusetts.

Market Opportunity

An analysis from ReportLinker states that the global cybersecurity market is expected to grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving cyber security market growth, according to the report.

A lack of cybersecurity professionals and the budget constraints among SMBs and start-ups in developing economies are expected to hinder market growth. Cybercriminals are using automated techniques to attack SMBs’ networks to take advantage of their weak security infrastructures. To save money, time and resources, SMBs are seeking cybersecurity solutions.


Enclave expands upon SideChannel’s cybersecurity service offerings by solving a pervasive network security problem with a simple tool.

A comprehensive cloud and network security solution, Enclave enables IT teams to contain breaches faster, reduce network outages, minimize latency and strengthen overall security defense.

Enclave creates the foundation for a Zero Trust network security model IT can build upon.

With Enclave, IT can easily segment their company’s network, organize personnel and computing devices at the employee workload level, and implement security controls across all network segments.

Enclave was designed and purpose built to serve the growing security needs of SMBs, a traditionally underserved market that is more prone to cyberattacks but has limited protection due to smaller budgets, inadequate IT security staffing and a lack of cybersecurity awareness among top executives.

Enclave is an affordable and effective network security solution that shrinks the attack surface area exposed to a cyber intruder and significantly reduces the amount of effort required to operate securely.

Management Team

Brian Haugli is CEO of SideChannel. He has led programs for the U.S. Department of Defense, the Pentagon, and Fortune 500 companies. He is an expert on National Institute of Standards and Technology guidance, threat intelligence implementations and strategic organizational initiatives. He is a professor at Boston College, Woods College of Advancing Studies Master’s Program in Cybersecurity. He is also a contributing author for the Wiley book ‘Cybersecurity Risk Management’.

Ryan Polk is CFO at SideChannel. He has been the principal of Perissos Partners, an executive consulting firm, since June 2017. He also served in executive roles in the portfolio companies owned by Lacy Diversified, with combined revenue approaching $2 billion. He served as the Vice President for Corporate Financial Planning and Analysis for Brightpoint, a publicly traded, Fortune 500 mobile device logistics company. He earned a bachelor’s degree in accounting and industrial management from Purdue University.

Nicholas Hnatiw is Chief Technology Officer at SideChannel. Prior to joining the company, he served as the technical director for network operations supporting U.S. Cyber Command, U.S. Intelligence Agencies and other Department of Defense research organizations. He was also the CEO of Loki Labs, a cyber security firm. He earned a bachelor’s degree in computer engineering and computer science at the University of Massachusetts, Amherst.

Bill Roberts is SideChannel’s CISO. He most recently served as the vice president, IS & CISO for Hologic Inc., a global medical device company, where he established cyber security and IT compliance programs. Prior to Hologic, he was vice president of information security for Cytyc Corporation, which was acquired by Hologic in 2007. At Cytyc, he managed global IT as the company grew from 140 employees to 1,500 and from $40 million in revenue to over $750 million.

SideChannel Inc. (OTCQB: SDCH), closed Tuesday's trading session at $0.14, even for the day, on 55,000 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.06/$0.18.

Recent News

Vision Energy Corp. (OTCQB: VIHDD)

The QualityStocks Daily Newsletter would like to spotlight Vision Energy Corp. (OTCQB: VIHDD).

Vision Energy (OTCQB: VIHDD), a forward-looking energy company developing carbon-reducedsolutions for the commercial, industrial and transportationsectors, is partnering with InvestorBrandNetwork (“IBN”) for itscorporate communications needs. IBN is a multifaceted financialnews and publishing company that services private and publicentities. According to the announcement, Vision Energy bringsimpressive experience to the energy space, including a proven trackrecord in site and asset procurement, and development andpermitting processes, as well as plant design and grid integrationto enable low-carbon energy production, supply and distribution.The company is focused on providing low-carbon energy solutionswith maximized yield. Vision Energy is committed to the idea thathydrogen and liquid carriers of hydrogen are the most reliablealternatives to fossil fuels. Vision Energy will collaborate withIBN to ensure news and information about the company will bedistributed over IBN’s network of more than 5,000 key syndicationoutlets as well included in newsletters and social media channels.IBN will also utilize its wire services, blogs and other outreachtools to increase and strengthen awareness of Vision Energypowerful approach to energy solutions. “In northwestern Europe,Vision Energy’s initial target market, demand for green hydrogenproduced by renewable energy is growing rapidly,” said IBN directorof client solutions Chris Johnson in the press release. “We’reexcited to customize our comprehensive suite of corporatecommunications solutions for the company as it advances developmentof its Green Energy Hub in the Netherlands – positioned as thefirst terminal in Europe focused on green and low-carbon energyproducts – while eyeing a total addressable market that’s on courseto hit €10 billion by 2050.” To view the full press release, visit

Vision Energy Corp. (OTCQB: VIHDD) (“Vision Energy”) is a forward-looking energy company developing carbon reduced solutions for the commercial, industrial and transportation sectors. Vision Energy is leveraging its team’s proven track-record in site and asset procurement, accelerating development and permitting processes, plant design, and grid integration to facilitate low-carbon energy production, supply and distribution. The company is pursuing reliable offtake relationships and operating partnerships with energy industry participants and end users seeking carbon abatements across feedstock and fuels. Vision Energy is committed to providing low carbon energy solutions with maximized yield, with projects designed to exploit existing gas and power infrastructure, to integrate and facilitate import and/or distribution of reduced-carbon energy to domestic and global supply chains.

The company believes that hydrogen and liquid carriers of hydrogen are the most reliable alternatives to fossil fuels. Hydrogen is anticipated by many energy analysts to become more widely competitive as an alternative mobile energy source as early as 2030, as economies of scale drive down costs.

According to the International Energy Agency report ‘Hydrogen in North-Western Europe (2021)’, the region is well placed to lead hydrogen adoption as a clean energy source. Today, this region comprises approximately 5% of global hydrogen demand and 60% of European demand. Moreover, the region is home to the largest industrial ports in Europe, where much of this hydrogen demand is located, and presents a well-developed natural gas infrastructure connecting these ports with other industrial hubs. This gas network could be partially repurposed to facilitate hydrogen delivery from production sites to demand centers. Governments in this region also have ambitious goals for greenhouse gas emissions reduction and there is strong political interest in hydrogen as a pathway to maintaining industrial activity in the region.

Vision Energy is based in Jersey City, New Jersey.


Through wholly owned subsidiary Evolution Terminals BV, Vision Energy is pioneering a Green Energy Hub development project for the import, storage and distribution of low-carbon renewable fuels and hydrogen carriers, strategically located in the North Sea port of Vlissingen at the mouth of the Westerschelde estuary in the Netherlands. This Green Energy Hub is positioned to be the first terminal in Europe focused on green and low-carbon energy products.

Vision Energy is at an advanced stage of planning for the construction of its Green Energy Hub and is on schedule to file for the remaining construction and environmental permits by December 2022. The Green Energy Hub design is capable of receiving seagoing vessels, barges and coasters, served by a dedicated deep-water jetty as well as rail and truck loading infrastructure that will enable direct access to purpose-built storage and handling facilities for low-carbon fuels and hydrogen carriers, including ammonia, methanol and liquid organics. Phase 1 capital expense is estimated at approximately €450 million, including jetty infrastructure, and will provide for up to 400,000 cubic meters (CBM) of storage capacity with land already secured for future expansion.

Market Opportunity

In Northwestern Europe, the market for green hydrogen, or hydrogen produced by renewable energy, is growing rapidly. The current hydrogen demand projections outstrip the scheduled production for the next five to 10 years.

The company believes that all producers will face high demand. Moving beyond its initial Green Energy Hub, Vision Energy is focused on countries where governments support a regulatory standard that promotes hydrogen production and consumption. Many governments have established various incentives and financial mechanisms to accelerate and promote the use of hydrogen as a renewable energy source.

The EU, through its European Green Deal, has set an objective to become climate-neutral by 2050, implying the near total phase-out of fossil fuels in the EU energy system, and many countries are working to put in place subsidy programs for the development of green hydrogen facilities in anticipation of this goal.

Vision Energy projects its total addressable market at €10 billion by 2050.

Management Team

Andrew Hromyk is CEO of Vision Energy. He has supported and operated chemical and energy operations in the Permian Basin, central and south Texas, Arkansas, Alberta and internationally. An active investor, he has been involved with companies developing a diverse range of technologies, from enhanced and conventional hydrocarbon recovery processes to wireless infrastructure. He has participated in numerous industrial and commercial real estate developments. He also has served as a director of several private companies that became publicly traded on Nasdaq, NYSE and TSX. He studied economics at Chaminade University and the University of British Columbia.

Arron Smyth is Executive Vice President of Corporate Development at Vision Energy. He has more than 18 years of experience in financial services, investment banking, business leadership and operations in both developed and emerging markets. Since 2018, he has been Managing Director Europe for the First Finance group of companies, developing and supporting the group’s private equity investments and projects, including Evolution Terminals, the Netherlands-based developer of tank terminal and port infrastructure for the bulk storage and handling of clean and sustainable energy products.

Matthew Hidalgo is CFO of Vision Energy. He has over 15 years of experience in accounting, operations, finance, corporate restructuring and integrating acquisitions. He is a Managing Partner at Turquino Equity LLC, a private equity investment firm. Formerly, he was the controller and operations manager for the largest subsidiary of WPCS International Incorporated, managing over $30 million in annual revenue. Prior roles included managing accounting functions for several Australian subsidiaries. After graduating from Penn State with a bachelor’s degree in accounting, he began his career at PricewaterhouseCoopers.

Vision Energy Corp. (OTCQB: VIHDD), closed Tuesday's trading session at $11, off by 2.1352%, on 198,790 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.25/$19.01.

Recent News

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF)

The QualityStocks Daily Newsletter would like to spotlight EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF).

EverGen (TSX.V: EVGN) (OTCQB: EVGIF), Canada’s renewable natural gas (“RNG”) infrastructure platform,has released its financial results and corporate update for thethree- and nine-month periods ended Sept. 30, 2022. The Q3 reportmilestones include quarterly revenue numbers that were in line withlast year, poised for growth with core expansion projects underconstruction on schedule and on budget; a signed term sheet for along-term RNG offtake agreement at Fraser Valley Biogas (“FVB”);the completed acquisition of GrowTEC and construction of RNGexpansion reaching 80% completion; secured funding for EVGN’s coreRNG expansion projects, including a signed term sheet for a $31million senior term loan; and the groundbreaking of the FVBexpansion project. Specific financial numbers (all amounts are inCanadian dollars) show cash and cash equivalents of $12.8million post-Capex spend of $3.5 million and $1.5 million ofinsurance proceeds received; revenues of $2 million, up from $1.9million in Q3 2021; net income loss of ($1.8) million; and adjustedEBITDA of $0.7 million, which was in line with Q3 2021 results of$0.8 million, despite a carryover impact from flood-related costsas well as increased general and administrative costs related tofuture growth. The company has scheduled a Zoom earnings conferencecall, which will be held today at 10 a.m. ET. EverGen CEO ChaseEdgelow will host the call. “It is an exciting time for EverGenwith strong momentum in the RNG market and as one of the firstmovers in Canada in terms of consolidating assets across thecountry,” said EverGen CEO Chase Edgelow in the press release. “Weare thrilled with the progress at our core RNG expansion projectsthat, once producing, will see us jump from C$3 million to C$13million in run rate EBITDA and are fully funded. With our GrowTECfacility commissioning imminently and construction at Fraser ValleyBiogas underway, we are anticipating a strong start to 2023.” Toparticipate in the zoom call, visit To view the full press release, visit

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) is developing Canada’s Renewable Natural Gas Infrastructure Platform, starting on the west coast in British Columbia. The company is combating climate change and helping communities contribute to a sustainable future by acquiring, developing, building, owning and operating a portfolio of renewable natural gas (RNG), waste-to-energy, and related infrastructure projects.

While EverGen is currently focused on British Columbia, its continued growth is expected across other regions of North America. RNG is produced differently than conventional natural gas, without drilling wells. RNG is derived from biogas, which is captured from decomposing organic waste in landfills, food waste, agricultural waste matter and wastewater from treatment facilities. This waste feedstock is supplied to an anaerobic digester which contains bacteria that breaks down organic matter in the absence of oxygen. The resulting biogas is captured and cleaned to create carbon neutral or carbon negative RNG to be used by the existing North American gas pipeline grid. By capturing these emissions and transforming them into RNG, then combusting into CO2, the overall greenhouse gases (GHG) impact is materially less potent than allowing natural decomposition to release methane into the atmosphere. Liquid and solid digestate matter is a byproduct of the RNG production process and is used as fertilizer and in other applications.

EverGen operates three projects in British Columbia. The company was incorporated in 2020 and went public in 2021, with its common shares listed on the TSX Venture Exchange under ticker symbol ‘EVGN’. In February 2022, EverGen’s common shares began trading on the OTCQB Venture Market in the U.S. under ticker symbol ‘EVGIF’. The company is headquartered in Vancouver.

Portfolio Projects

Fraser Valley Biogas is one of three projects in EverGen’s portfolio. Located in Abbotsford, British Columbia, the facility has been digesting manure and off-farm organics since 2011 and was the first agricultural digester in Canada to produce RNG. The RNG generated through this project is part of a FortisBC program to supply renewable gas to homes, businesses and other customers. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced. EverGen acquired Fraser Valley Biogas early in 2021 and is currently enhancing and expanding the facility. These optimization projects resulted in record production during the month of September 2021, supporting the growing demand for RNG in British Columbia. Optimization activities contributed an additional 18% of RNG production for September and a 9% higher year-to-date production compared to the previous year. The facility produces approximately 80,000 gigajoules of RNG, enough to heat more than 1,000 homes for a year.

Net Zero Waste Abbotsford, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and RNG expansion project. The British Columbia Utilities Commission recently approved a 20-year offtake agreement between the facility and FortisBC, an electricity and gas utility. Under this agreement, FortisBC will purchase up to 173,000 gigajoules of RNG annually for injection into its natural gas system upon completion of an anaerobic digester project at Net Zero Waste Abbotsford. Once construction is complete, this project is expected to produce enough energy to meet the needs of more than 1,900 homes.

Sea to Sky Soils, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and potential future RNG expansion project which has been operating near Pemberton, British Columbia, on Lil’wat Nation land since 2012. The Lil’wat Nation is a key partner and supporter of the facility, which has employed a majority of its staff from the First Nation since inception. The Sea to Sky Soils facility processed approximately 160 percent of its forecast tonnage in the second half of 2021. In total, Sea to Sky Soils processed approximately 36,000 tons of organic waste in 2021. The facility is working with the Ministry of Environment to expand its operational capacity in 2022. EverGen has partnered with local municipalities – including Metro Vancouver and the municipality of Pemberton – for the delivery of additional organic waste to the facility. The facility is an important part of EverGen’s RNG infrastructure platform and serves as a source of valuable feedstock to support the company’s existing and future operations.

Market Outlook

A report from Global Market Insights states that the biogas market is projected to see significant growth over the next few years, driven by a shifting preference to utilize biogas to reduce emission levels from traditional fuels. Escalating RNG usage by gas utilities as a sustainable and low carbon alternative to supply heat and electricity in industries and buildings will further stimulate growth. RNG is increasingly deployed across the transport sector, especially for heavy vehicles and vessels, to abate GHG emissions.

Many North American gas utilities have set RNG targets of 5% to 15% of production by volume in 2030, compared to less than 1% by volume in 2020. FortisBC has a goal of including 15% RNG in its gas supply by 2030. EverGen believes this presents a potential C$16 billion+ opportunity for RNG producers.

Management Team

Chase Edgelow is co-founder and CEO at EverGen. He has over 15 years of specialized private investment, finance, and technical expertise in the energy and infrastructure sectors. His background is as a Facilities Engineer with Petro-Canada, independently managing energy infrastructure capital projects located in western Canada. He holds a Professional Engineer designation from the province of Alberta.

Mischa Zajtmann is co-founder and President at Evergen. He has 15 years of experience providing consulting and management for Canadian and American companies in the natural resources and energy space. He is a corporate securities lawyer who began his career at Blake, Cassels & Graydon LLP. His J.D. is from the University of Saskatchewan Law School. He’s a member of the British Columbia Bar.

Sean Mezei is COO at EverGen. He has 20 years of experience in the RNG industry, having served previously as the president of Greenlane Biogas and as a senior manager at QuestAir, and founder and president of Dekany Consulting. He was a co-chairman of the American Biogas Council’s RNG working group for six years. He has been a Registered Professional Engineer in the province of British Columbia since 1994.

Natasha Monk is CFO at EverGen. She is a CPA with 12 years accounting, financial reporting, and tax experience in public practice and industry. She is currently a partner at Affirm LLP, where she advises and consults to a wide variety of companies in multiple industries across public and private sectors. Prior to joining EverGen, she worked at KPMG. She graduated from the University of Calgary.

EverGen Infrastructure Corp. (OTCQX: EVGIF), closed Tuesday's trading session at $1.615, off by 1.5304%, on 3,400 volume. The average volume for the last 3 months is 3,400 and the stock's 52-week low/high is $1.365/$4.21.

Recent News

Correlate Infrastructure Partners Inc. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Infrastructure Partners Inc. (OTCQB: CIPI).

With the recently passed Inflation Reduction Act, Correlate looksto achieve significant net gains

The company just posted a significant revenue bump from $236,690 inQ2 2022 to $2,313,577 in Q3 2022, plus shows project opportunitiesof up to $194 million

Todd Michaels, Correlate’s CEO, has also noted the company’sfinalized M&A plans through Q2 2023, integral to scaling up thesize and overall value of its projects and further growing revenue

In September, the company entered into a non-binding letter ofintent to acquire Vermont-based Aegis Renewable Energy Inc., which,once finalized, will present Correlate with new strategic abilitiesto explore the bludgeoning Northeast renewable energy market

Correlate Infrastructure Partners (OTCQB: CIPI), a tech-enabled development, finance, and fulfillment platform fordistributed energy solutions across North America, just releasedits financial report for the third quarter of the 2022 financialyear (“Q3 2022”). Of obvious note was the significant bump inrevenue from $236,690 in Q2 2022 to $2,312,577. While speakingduring the announcement, Todd Michaels, Correlate’s CEO, lauded thecompany’s performance and expressed his optimism for the company’sfuture, particularly with the enactment of the Inflation ReductionAct (

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), formerly Triccar Inc., through its two subsidiaries, Correlate and Solar Site Design, offers a complete suite of proprietary clean energy assessment and fulfilment solutions for the commercial real estate industry. The company believes scaling distributed clean energy solutions is critical in mitigating the effects of climate change. CIPI is at the forefront in creating an industry-leading energy solution and financing platform for the commercial and industrial sector. The company sees tremendous market opportunity in reducing site-specific energy consumption and deploying clean energy generation and energy efficiency solutions at scale.

The opportunity exists to remove friction between today’s legacy finance process and the needed clean-energy upgrades developed within the company’s program technologies. For the U.S. to reach its 2050 carbon goals, 200,000 commercial buildings must be retrofitted every year until that date. That represents approximately a 5-10x increase over the 2022 industry process run rate.

CIPI announced completion of its acquisition of 100% of the equity of Correlate Inc. and Loyal Enterprises LLC dba Solar Site Design on December 28, 2021. The company notes these acquisitions occurred at a key inflection point of its growth. CIPI currently enjoys channel and sales partnerships with Fortune 250 companies and a strong, proven industry network.

The company’s transparent, leading-edge model changes value delivery for both facility owners and proven solution providers seeking scale. CIPI believes its rapid growth is due to industry demand for actionable, cashflow positive energy programs and the underlying carbon reduction mandates taking effect globally.

CIPI has filed with the SEC for a name change to Correlate Infrastructure Partners Inc., which will more closely reflect its new platform and growth focus. The company has been aggressively moving to rebrand, with efforts including a revised website, investor presentation materials and an investor relations awareness campaign. The company’s shares will continue to trade on the OTCQB Venture Market under the current ‘CIPI’ ticker symbol until changes are approved.


Correlate, founded in 2015, is a portfolio-scale development and finance platform offering commercial and industrial facilities access to clean electrification solutions focused on locally-sited solar, energy storage, EV infrastructure, and intelligent efficiency measures. Its unique data-driven approach is powered by proprietary analytics, concierge subscription services, and a highly scalable national fulfillment network to help building owners profit from fully funded, turnkey decarbonization and facility health programs. The platform is designed for commercial and industrial real estate owners seeking to significantly improve net operating income while meeting carbon reduction goals. The platform provides energy programs for commercial property portfolios and requires no upfront capital. Client organizations reduce their risk and generate more profits by leveraging Correlate’s unique payment programs to put more cash in the bank. Deploying Correlate’s strategic energy programs and energy management systems allows property-owning organizations to complete big energy changes across their portfolios.

Solar Site Design, founded in 2013, is a U.S. Department of Energy Sunshot Catalyst winner that provides customer acquisition and project development tools for the commercial solar industry. Its commercial marketplace platform connects highly qualified project opportunities to leading solar construction companies nationwide. The Solar Site Design platform gives commercial and industrial property owners access to the best price for a commercial solar system. Commercial solar analysts provide property owners a site assessment and working project proposal. Solar Site Design’s team of solar engineers finalize the design while approved financing providers help clients explore financing options for their projects. Then, approved contractors in Solar Site Design’s Marketplace bid on the projects, ensuring commercial and industrial property owners get the best estimates for their projects. Solar Site Design’s marketplace process promotes transparency and fair pricing. Its team of experts has nearly 20 years of experience in the solar industry. Only reputable, experienced, certified (NABCEP), licensed, bonded and insured contractors are accepted into the Solar Site Design Marketplace.

Market Outlook

CIPI is in a rapidly growing market with a unique offering to address a total market of more than 5.9 million commercial buildings in the United States, according to the U.S. Energy Information Administration. Currently, the company’s wholly owned subsidiaries, Correlate and the Solar Site Design, have an opportunity pipeline of over $100 million in commercial projects with more than $20 million in awarded backlog. According to the Rocky Mountain Institute, portfolio energy optimization is a $290 billion market in the United States driving deep financial savings and energy efficiency across the commercial sector.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon, and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings. Yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which has very different needs than traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue known as the “split incentive”, unlocking the majority of the addressable market.

Management Team

CIPI has in place a nationally recognized management team that has been active in the energy market since 2005.

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

David Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jason Loyet is VP of Commercial Sales of Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Deke Welling is Head of Project Development and Fulfillment Services at Correlate Inc. He has over 19 years’ experience in the energy industry with an emphasis on renewables and energy efficiency over the past seven years. Prior to entering the renewables sector, Mr. Welling was the CEO of Welling Resources, an energy development company focused on the exploration of oil and natural gas reserves in the U.S. It was this experience that led him into the renewables sector and leading a charge for more sustainable resources. Additionally, Mr. Welling also served as the CEO of Circle L Solar Inc., a top 100 solar installer in the United States since 2016. Through his leadership, Circle L Solar experienced a growth rate of over 2,250% from 2016 to 2019, resulting in his company being listed on the Inc. 5000 list of the fastest growing private companies in the U.S. (Rank #176) and being named ‘Top Energy Company’ and ‘Entrepreneur of Year for the Energy Industry’ by the American Business Awards® in 2019 and again for ‘Entrepreneur of the Year’ in 2021.

Kevin Warren is Head of Construction and Development Engineering at Correlate Inc. He is a solar veteran with over 12 years of experience in the field. Prior to co-founding CLS, Mr. Warren was the owner of Beacon Consulting and has originated, consulted, designed and/or engineered over 122 MW of PV installations ranging from small commercial to utility scale projects throughout Texas, California, Colorado and North Carolina. He holds a Photovoltaic Technical Sales Professional Certification from the North American Board of Certified Energy Practitioners and certifications from Solar Energy International in PV Installation, PV Technical Sales, PV battery-based design, PV design and engineering, and PV operations and maintenance. Along with PV expertise, Mr. Warren is a LEED Green Building Associate, a certified building analyst from the Building Performance Institute, a Certified Renewable Energy Professional from the Association of Energy Engineers and holds a designation in High-Performance Sustainable Buildings from the BOMI Institute. He studied Electrical Engineering at the University of Texas at Arlington.

Tom Kunhardt is Director of Customer Success at Correlate. He previously held a similar position at Clean.Tech and was Corporate Trainer, Learning & Development, at NRG Energy. He has 15 years of experience in the solar and clean energy industries helping homeowners and businesses find solutions to their energy needs. He holds a bachelor’s degree from the University of Massachusetts.

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), closed Tuesday's trading session at $1.3, off by 10.3448%, on 2,600 volume. The average volume for the last 3 months is 2,600 and the stock's 52-week low/high is $0.32/$3.25.

Recent News

Freight Technologies Inc. (NASDAQ: FRGT)

The QualityStocks Daily Newsletter would like to spotlight Freight Technologies Inc. (NASDAQ: FRGT).

Freight Technologies (NASDAQ: FRGT), a technology company based on its custom-developed Fr8Appplatform, which is powered by AI and machine learning and whichoffers a real-time portal for B2B cross-border shipping anddomestic shipping within the United States-Mexico-Canada (“NAFTA”)region, is reporting on its third-quarter 2022 revenue for theperiod ended Sept. 30, 2022. According to the report, the companyshowed revenue growth of 38% over the same period last year,reporting revenue of $7.7 million for this quarter compared to $5.6million for Q3 2021. The company also announced an adjustment infull-year 2022 revenue guidance, increasing it to $29 to $30 30million, up an estimated 25% to 40% from Fr8App’s 2021 full-yearrevenue of $21.5 million. “Third-quarter 2022 revenue increased 38%on a year-ago quarter basis and 32% on a year-over-year basis,”said Fr8Tech CEO Javier Selgas in the press release. “The growthreflects greater traction in each of our dedicated capacity productFr8Fleet and a strong performance from our cross-border group. Itis also the first quarter in which we stopped servicing our legacybroker accounts, consistent with our strategy of pursuing keyrelationship accounts on the shipper end. Fr8App continues to offermany advantages, including improved operational efficiencies,additional security benefits and the possibility of end-to-endpaperless shipping, that benefit both shipper and carriercustomers. Our strategy of pursuing businesses complementary to ourcross-border business for key relationship accounts is also showingpositive results. Some of our key accounts in Fr8Fleet are activelypursuing cross-border opportunities with us in addition toexpanding their Fr8Fleet requests from the company.” To view thefull press release, visit

Freight Technologies Inc. (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process, providing a platform for B2B cross-border shipping in the NAFTA region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road shipping.

Freight Technologies, formerly known as Hudson Capital Inc., assumed its current name and ticker symbol on May 27, 2022. Its primary operating subsidiary and its marketplace are known as Fr8App, and it conducts operations throughout North America under the names of Fr8App and/or Freight App. The company is headquartered in Houston, Texas, with multiple locations across the U.S. and Mexico.

The Fr8Tech Solutions Suite

Fr8Tech leverages artificial intelligence to provide cloud-based platforms aimed at automating the over-the-road transportation process, effectively reducing human touch points and expediting load booking times. The company’s suite of solutions includes:

  • Fr8app – A B2B marketplace powered by AI and Machine Learning offering a real-time broker portal to connect shippers with qualified carriers
  • Fr8Radar – A tracking solution providing shippers and carriers real-time locational data via Fr8app’s mobile solution or through integration with third-party GPS alternatives
  • Fr8TMS – A transportation management system designed to help shippers manage their freight and all of the documents involved in shipping transactions, including invoices, customs documents, confirmation rates and proof of deliveries
  • Fr8FMS – A fleet management system allowing transportation companies to better manage their fleets, reduce operational costs and provide better service to their customers
  • Fr8Data – A data solution offering real-time dashboards and reports to shippers and carriers in an effort to increase visibility and control while supporting better business decisions
  • Fr8Fleet – A platform that provides private fleet management, enabling large corporate shippers to purchase dedicated capacity secured by Fr8app in exchange for a fixed fee

Commitment to the Environment

Through its core focus on technology, Fr8Tech seeks to reduce the carbon footprint of the logistics industry. Its solutions aim to minimize empty miles for transportation firms and reduce overall paper consumption.


Fr8University is an educational program offering classroom and on-the-job training for Fr8Tech team members. Through the program, employees learn in-depth business fundamentals and applications along the truckload freight industry value chain.

Led by corporate educator Mario Mena, Fr8University is designed as an investment in the company’s human capital, providing an opportunity to communicate Fr8Tech’s corporate culture while accelerating operational growth.

Market Outlook

Fr8Tech’s established foothold in Mexico is key to its current efforts to promote sustainable growth in the cross-border shipping industry. Ongoing disruption in U.S.-Chinese trade relations have strengthened Mexico’s status as the largest trading partner of the U.S., with cross-border annual freight spending estimated at $385 billion according to data from the U.S. Department of Transportation. Annual domestic shipping in Mexico is estimated at $34 billion, while annual domestic shipping in the U.S. is estimated to total $732 billion.

Despite the size of this industry, fragmentation and inefficiencies prevail in the space. Thousands of legacy brokers, tens of thousands of shippers and hundreds of thousands of carriers still rely on outdated systems to arrange transport, spending hours on the phone negotiating pricing, waiting days to find trucks and drivers, preparing and printing forms, and operating without tracking or visibility. Add in cross-border complexity relating to customs and additional paperwork, and you have an industry ripe for technological disruption.

Fr8Tech’s recent revenue growth trends have highlighted the company’s efforts to capitalize on this opportunity. In 2021, Fr8Tech achieved revenues of $21.5 million, marking a year-over-year increase of 134%. The company issued revenue guidance for fiscal 2022 of $40 million in a February 9, 2022, press release, which would account for a further 86% year-over-year increase.

Management Team

Javier Selgas is CEO and a Director of Freight Technologies Inc. and Freight App Inc. He brings to the company over 15 years of experience developing technology and digital marketing strategies, including serving as Country Manager for Osigu, Spain, and as head of AJEgroup’s IT division for the Asia-Pacific region. Prior to joining Fr8Tech, Mr. Selgas founded digital marketing agency Lanzadera Online. He has also served as an IT consultant to major corporations, including Endesa and Ibermatica.

Mike Flinker is President of Fr8Tech. He has over four decades of experience in the transportation industry, with 30+ years focused on cross-border logistics. Prior to joining Fr8Tech, Mr. Flinker founded FLS Transportation, the largest cross-border logistics company in Canada. He also previously held positions with Clarke Transport Inc., Canadian Pacific and Reimer Express Inc. (a division of Roadway Express).

Paul Freudenthaler is the company’s CFO and Secretary to the company Board. He has over 30 years of financial expertise, having previously served as CFO for several leading companies across multiple countries, including Macquarie in Mexico, Old Mutual in Latin America and Ascentium Capital in the U.S. Mr. Freudenthaler’s experience include leadership roles from which he guided IPOs and M&A transactions.

Luisa Lopez is COO of Fr8Tech. She brings to the company 25+ years of management experience in logistics, supply chain, operations and customer service. Ms. Lopez previously served as a Director of Landstar, where she was responsible for commercial and client development strategies in the Mexican market. Additionally, she managed more than 2,000 transport units specialized in staff and school mobility while with Traxion in Mexico.

Freight Technologies Inc. (NASDAQ: FRGT), closed Tuesday's trading session at $0.3347, off by 5.7183%, on 1,464,565 volume. The average volume for the last 3 months is 1.393M and the stock's 52-week low/high is $0.1799/$8.734.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.